Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Construction in Progress (2020 - 2022)

Marker Therapeutics (MRKR) has disclosed Construction in Progress for 3 consecutive years, with $4.1 million as the latest value for Q1 2022.

  • On a quarterly basis, Construction in Progress changed N/A to $4.1 million in Q1 2022 year-over-year; TTM through Mar 2022 was $4.1 million, a N/A change, with the full-year FY2021 number at $2.2 million, down 67.27% from a year prior.
  • Construction in Progress was $4.1 million for Q1 2022 at Marker Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $6.8 million in Q4 2020 to a low of $2.2 million in Q3 2021.
  • A 3-year average of $3.8 million and a median of $3.4 million in 2020 define the central range for Construction in Progress.
  • Biggest YoY gain for Construction in Progress was 52.17% in 2021; the steepest drop was 67.27% in 2021.
  • Marker Therapeutics' Construction in Progress stood at $6.8 million in 2020, then crashed by 67.27% to $2.2 million in 2021, then surged by 83.72% to $4.1 million in 2022.
  • Per Business Quant, the three most recent readings for MRKR's Construction in Progress are $4.1 million (Q1 2022), $2.2 million (Q4 2021), and $2.2 million (Q3 2021).